Michael DiGiovanna, MD, PhD
Professor of Internal Medicine (Medical Oncology); Chair, Breast Cancer Tumor Board, Yale Cancer Center; Curriculum Director, Office of Education; Thread Leader, Pharmacology, Office of Education; Master Course Co-Leader, Office of Education
Biography
Research & Publications
Patient Care
News
Locations
Appointments
Biography
Dr. DiGiovanna is a native of Long Island, NY, who graduated from Cornell University in 1984 with a B.A. and a double major in the fields of biochemistry and music. He attended Yale University from 1984 through 1990 where he was earned the MD and PhD degrees, with his PhD in Pharmacology. He continued his post-graduate training at Yale, performing internship and residency in Internal Medicine, a research post-doctoral fellowship, and a clinical fellowship in Medical Oncology. He is currently an attending physician in Medical Oncology and Professor of Medicine (Oncology) and Pharmacology at Yale University. His clinical specialty is breast cancer and he conducts both clinical and laboratory-based research. His translational laboratory research focuses on signal transduction in breast cancer. He also has had many leadership roles in education at the Yale School of Medicine, including current roles as Co-Director of the Pre-Clerkship Curriculum, Pharmacology Thread Leader, and Co-Leader of the Genes & Development Master Course. Learn more about Dr. DiGiovanna>>
Education & Training
- FellowYale School of Medicine (1997)
- Postdoctoral FellowYale University (1997)
- ResidentYale University School of Medicine (1994)
- PhDYale University (1990)
- MDYale University (1990)
- BACornell University, Biology (Biochemistry), Music (1984)
Activities
- Current chemo-treatments and protocols for breast cancer managementNew York, NY, United States 2019Current chemo-treatments and protocols for breast cancer management
- Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an Oncotype Dx Recurrence Score (≤25)San Antonio, TX, United States 2019Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an Oncotype Dx Recurrence Score (≤25)
- Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancerSan Antonio, TX, United States 2019Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer
- Adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysisSan Antonio, TX, United States 2019Adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
- Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINESan Antonio, TX, United States 2018San Antonio Breast Cancer Symposium
- Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)Chicago, IL, United States 2018American Society of Clinical Oncology, Annual Meeting
- An Evening Symposium on Breast Cancer – Incorporating Emerging Practice Options for HER2 and ER+ Breast CancerTampa, FL, United States 2017An Evening Symposium on Breast Cancer – Incorporating Emerging Practice Options for HER2 and ER+ Breast Cancer
- Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fouorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancerChicago, IL, United States 2017American Society of Clinical Oncology, Annual Meeting
- Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (dd AC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A phase I/II trialChicago, IL, United States 2017American Society of Clinical Oncology, Annual Meeting
- Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?Westwood, KS, United States 2017Southwestern Surgical Congress, Annual Meeting
- A novel approach to the medical student hematology curriculumSan Diego, CA, United States 2016American Society of Hematology, Annual Meeting
- Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot studyChicago, IL, United States 2016American Society of Clinical Oncology, Annual Meeting
- Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast Cancer Endocrine Therapy Adherence (BETA) Pilot StudySan Antonio, TX, United States 2015San Antonio Breast Cancer Symposium
- Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH)San Francisco, CA, United States 2015American Society of Clinical Oncology Breast Cancer Symposium
- A phase II trial of neoadjuvant aromatase inhibitor therapy and the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and a low/intermediate risk Oncotype Dx Recurrence Score (≤ 25)Chicago, IL, United States 2015American Society of Clinical Oncology, Annual Meeting
- Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapyChicago, IL, United States 2015American Society of Clinical Oncology, Annual Meeting
- Mutation-based treatment recommendations from next generation sequencing data: A comparison of web toolsChicago, IL, United States 2015American Society of Clinical Oncology, Annual Meeting
- Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencingPhiladelphia, PA, United States 2015American Association for Cancer Research, Annual Meeting
- Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumorsChicago, IL, United States 2014American Society of Clinical Oncology, Annual Meeting
- Training medical students and faculty to have constructive feedback discussions about coursesNew Haven, CT, United States 2014Northeastern Group on [Medical] Educational Affairs, Spring Annual Rretreat
- Predictors of Use of Adjuvant Chemotherapy and Overall Survival Outcomes in Elderly Breast Cancer PatientsPhoenix, AZ, United States 2014Society of Surgical Oncology Cancer Symposium
- Characterization of the relationship between pathologic complete response from neoadjuvant treatment and survival measures in breast cancer subtypes: Implications for study designSan Antonio, TX, United States 2013San Antonio Breast Cancer Symposium
- Patterns of the use of primary systemic therapy in the United StatesSan Antonio, TX, United States 2013San Antonio Breast Cancer Symposium
- Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experienceSan Antonio, TX, United States 2013San Antonio Breast Cancer Symposium
- Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab therapySan Antonio, TX, United States 2013San Antonio Breast Cancer Symposium
- The impact of survivorship care plans on knowledge among breast cancer survivorsSan Francisco, CA, United States 2013American Society of Clinical Oncology Breast Cancer Symposium
- Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancerChicago, IL, United States 2013American Society of Clinical Oncology, Annual Meeting
- Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG studyChicago, IL, United States 2013American Society of Clinical Oncology, Annual Meeting
- Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancerChicago, IL, United States 2013American Society of Clinical Oncology, Annual Meeting
- Neoadjuvant weekly nap-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) + B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): a BrUOG studyChicago, IL, United States 2012American Society of Clinical Oncology, Annual Meeting
- A phase I study of biweekly capecitabine and the histone deacetylase inhibitors (HDACi) vorinostat in advanced breast cancer (BC)Chicago, IL, United States 2011American Society of Clinical Oncology, Annual Meeting
- Exploring a Therapeutic Role for IGF1R Inhibitors in Triple-Negative Breast CancerSan Antonio, TX, United States 2010San Antonio Breast Cancer Symposium
- Trastuzumab (H) and Rapamycin (R) for treatment of HER-2 overexpressing metastatic breast cancer (BC) with prior disease progression on H based therapy: Safety and pharmacodynamic (PD) resultsSan Antonio, TX, United States 2010San Antonio Breast Cancer Symposium
- Evaluation of the mechanism of action of histone deacetylase inhibitors (HDACi) in the treatment of breast cancer (BC)Hollywood, FL, United States 2010ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer
- Self-Management and Transitions in Palliative CareQuebec City, QC, Canada 201018th International Congress on Palliative Care
- Therapeutic Targeting of the Interactions Between Hormone and Growth Factor Receptor SignalingTroy, NY, United States 2010New Frontiers in Breast Cancer Research and Prevention
- A phase Ι study of the mTOR inhibitor sirolimus (Rapamycin, R) in combination with nanoparticle albumin-bound paclitaxel (nab-P)Chicago, IL, United States 2010American Society of Clinical Oncology Annual Meeting
- Blocking Cross-Talk Between ER and Growth Factor PathwaysNew York, NY, United States 2009Physicians’ Education Resource, Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant
- What is breast cancer?West Haven, CT, United States 2009"Hope, Not Fear", Fourth Annual Breast Cancer Community Forum
- Association between HER2/neu overexpression and calcifications in breast cancerOrlando, FL, United States 2009American Society of Clinical Oncology, Annual Meeting
- Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biologyOrlando, FL, United States 2009American Society of Clinical Oncology, Annual Meeting
- Insulin-like Growth Factor Receptor: Role in Breast CancerRiyadh, Riyadh Province, Saudi Arabia 2008First Saudi Oncology Society International Breast Cancer Conference
- Breast cancerRiyadh, Riyadh Province, Saudi Arabia 2008Medical Files
- What is breast cancer?West Haven, CT, United States 2008"Hope, Not Fear", Third Annual Breast Cancer Community Forum
- Neoadjuvant chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameterChicago, IL, United States 2008Society of Surgical Oncology Annual Cancer Symposium
- Breast sentinel lymph node dissection (SLND) prior to preoperative chemotherapyColorado Springs, CO, United States 2007Western Surgical Association Annual Meeting
- Metastatic breast cancerNorth Haven, CT, United States 2007CTV Television Program
- Pre-clinical studies of combination targeted therapies in breast cancerNew Brunswick, NJ, United States 2007Cancer Center Grand Rounds
- Chemotherapy and Hormonal Therapy Advances in Breast CancerStamford, CT, United States 2006Physicians’ Education Resource, Emerging Trends in Oncology: Updates from 2006 AACR and ASCO Meetings
- Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC)Atlanta, GA, United States 2006American Society of Clinical Oncology, Annual Meeting
- Combinations of drugs that block HER2, ER and IGF1RHartford, CT, United States 2006Susan G. Komen Breast Cancer Foundation, “Breast Cancer: Survive and Conquer” Symposium
- Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cellsWashington, DC, United States 2006American Association for Cancer Research, Annual Meeting
- Herceptin as Adjuvant Therapy: A Dramatic Leap Forward in Improving the Cure Rate of Breast CancerNew Haven, CT, United States 2005Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium
- Targeting the HER2-ER cross-talk in breast cancerSunnybrook, AB, Canada 2004Sunnybrook Regional Cancer Centre Grand Rounds
- Comparison of HER-2 and topoisomerase II amplification with outcome after cyclophosphamide, doxorubicin and 5 FU-based chemotherapy for Stage II breast cancer (CALGB 8541/150013)New Orleans, LA, United States 2004American Society of Clinical Oncology, Annual Meeting
- Synergistic interactions between all-trans retinoic acid, Herceptin, and tamoxifen in BT-474 human breast cancer cellsOrlando, FL, United States 2004American Association for Cancer Research, Annual Meeting
- Targeting HER2 and ER in breast cancerKey Biscayne, FL, United States 2003American Cancer Society – Harry and Elsa Jiler-American Cancer Society Professors Meeting
- Phosphorylated/activated HER2 (P-HER2) as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer (MBC)Washington, DC, United States 2003American Association for Cancer Research, Annual Meeting
- Antitumor activity of combinations of tamoxifen and Herceptin in BT-474 human breast cancer cellsWashington, DC, United States 2003American Association for Cancer Research, Annual Meeting
- Adjuvant sequential dose dense doxorubicin, paclitaxel and cyclophosphamide (ATC) for high risk breast cancer (BC)Chicago, IL, United States 2003American Society of Clinical Oncology, Annual Meeting
- Activated (phosphorylated) HER-2/neu in breast cancerNew York, NY, United States 2002The Society for Applied Immunohistochemistry Symposium
- Use of Herceptin in breast cancerJasper, AB, Canada 2002The North Alberta Breast Cancer Program Symposium
- Management Options in Metastatic Breast CancerNew York, NY, United States 2002Centralized Tumor Conference/Grand Rounds
- Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neuOttawa, ON, Canada 2002Ottawa Regional Cancer Centre Grand Rounds
- Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neuKingston, ON, Canada 2002Kingston Regional Cancer Centre Lecture
- Activation state of HER-2/neu: Clinical implicationsBoston, MA, United States 2001Dana-Farber Cancer Institute Breast Cancer Conference
- Activation state of HER-2/neu: Clinical implicationsToronto, ON, Canada 2001Greater Toronto Area Breast Cancer and Lymphoma Update
- Activation state of HER-2/neu: Clinical implicationsCalgary, AB, Canada 2000Tom Baker Cancer Centre Grand Rounds
- Activation state of HER-2/neu: Clinical implicationsScottsdale, AZ, United States 2000The Canadian Oncology Leaders Conference
- The prognostic value of molecular marker expression in oral and oropharyngeal squamous cell carcinomaSan Francisco, CA, United States 2000The 5th International Conference on Head and Neck Cancer
- Signaling status of HER-2/neu as a prognostic factor in breast cancerAtlanta, GA, United States 2000Annual Meeting, The Department of Defense Breast Cancer Research Program Meeting
- Signaling status of HER-2/neu as a prognostic factor in breast cancerAtlanta, GA, United States 2000The Department of Defense Breast Cancer Research Program, Annual Meeting
- Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neuMeriden, CT, United States 2000Midstate Medical Center, John M. McIntyre Symposium
- Synergistic interactions between tamoxifen and HerceptinTMSan Francisco, CA, United States 2000American Association for Cancer Research, Annual Meeting
- Update on HER-2/neu: Clinical implications, Importance of Testing, Activated HER-2/neuNorwalk, CT, United States 2000Norwalk Hospital Cancer Center, Breast Cancer Conference
- ErbB-2, activated ErbB-2 and EGFR immunoexpression in breast cancersSan Antonio, TX, United States 1999San Antonio Breast Cancer Symposium
- Activation state of HER-2/neu: Clinical implicationsNew Orleans, LA, United States 1999American Society of Clinical Pathologists Meeting
- Breast cancer updateGlastonbury, CT, United States 1999The Claire C. Courtney Breast Cancer Foundation
- Activated erbB-2 immunodetection using PN2A: Biologic and prognostic associationsSan Antonio, TX, United States 1998San Antonio Breast Cancer Symposium
- How Breast Cancer ArisesNew Haven, CT, United States 1998Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium
- Pattern of tyrosine phosphorylation of Neu (HER-2/erbB-2) provides a model for breast tumorigenesis in transgenic miceNew Orleans, LA, United States 1998American Association for Cancer Research, Annual Meeting
- Activation of HER-2/neu in breast cancerWashington, DC, United States 1997The Department of Defense Breast Cancer Research Program, Annual Meeting
- Activation state of HER-2/neu: Clinical implicationsDavis, CA, United States 1997University of California, Davis, Oncology Grand Rounds
- Functional assay for HER-2/neu in invasive breast carcinoma demonstrates active signaling in a minority of cases with HER-2/neu overexpression. Clinicopathologic correlations.Washington, DC, United States 1996American Association for Cancer Research, Annual Meeting
- Activation State Specific Anti-p185neu/erbB2 Monoclonal Antibody Detects the Phosphorylated Receptor in Breast TumorsToronto, ON, Canada 1995American Association for Cancer Research, Annual Meeting
- Myeloid Differentiation Associated Protein Tyrosine Kinase Activity in a Murine Monomyelocytic Leukemia Cell LineSan Francisco, CA, United States 1989American Association for Cancer Research, Annual Meeting
- Measurement of Cytotoxicity and DNA Crosslinks Induced by Mitomycin C (MC) and MC-analogs in Aerobic and Hypoxic EMT6 CellsNew Orleans, LA, United States 1988American Association for Cancer Research, Annual Meeting
- In Vivo Effects of Recombinant Granulocyte-Macrophage Colony Stimulating Factor (rGM-CSF) in Cyclophosphamide (CTX) Treated MiceNew Orleans, LA, United States 1988American Association for Cancer Research, Annual Meeting
Honors & Recognition
| Award | Awarding Organization | Date |
|---|---|---|
| Alvan R. Feinstein Award | Yale School of Medicine | 2019 |
| Swebilius Translational Cancer Research Award | Yale University | 2006 |
| Women's Health Investigator Award | Ethel F. Donaghue Women's Health Investigator Program at Yale | 2005 |
| American Cancer Society Research Scholar Grant | American Cancer Society | 2002 |
| Angel of Hope Award | American Cancer Society | 2002 |
| Career Development Award | US Army Medical Research & Materiel Command Department of Defense | 1997 |
| Hoffman-La Roche Travel Award | American Association for Cancer Research | 1996 |
| Postdoctoral Fellowship Award | US Army Medical Research & Development Command Department of Defense | 1994 |
Professional Service
| Organization | Role | Date |
|---|---|---|
| Yale Department of Medicine, Search committee for Chief of Geriatrics | Search committee for Chief of Geriatrics | 2019 - 2020 |
| Yale Medical Oncology, Retreat Planning Committee | Planning committee for section retreat | 2019 - 2020 |
| Search Committee for Geriatrics Section Chief, YSM | Search Committee for Geriatrics Section Chief | 2019 - Present |
| Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven ASCO Review 2018 | Presenter for meeting review; Hosted by Yale, attended by regional audience | 2018 |
| JCO Precision Oncology | Reviewer | 2018 - Present |
| Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven ASCO Review 2017 | Meeting review; Hosted by Yale, attended by regional audience | 2017 |
| Education Policy and Curriculum Committee, YSM | As a YSM curriculum director, I serve on the EPCC which oversees all of medical education | 2016 - Present |
| Integrated Courses Review Committee, YSM | Chair | 2015 - Present |
| Course Directors Meetings | As Co-Director of the Pre-Clerkship Curriculum for YSM, I co-chair this monthly meeting of all YSM course and thread leaders | 2015 - Present |
| Genes & Development Master Course, YSM | Co-Leader of one of eight "Master Courses" that constitute the YSM pre-clerkship curriculum | 2015 - Present |
| LCME Academic Environment Subcommittee, YSM | Committee to address academic environment in preparation for LCME school review | 2014 - 2015 |
| Yale ASCO Review 2014: Highlights of the Annual Meeting | Meeting review; Hosted by Yale, attended by regional audience | 2014 |
| Yale Cancer Center Evening Oncology Series: Breast Cancer, “Highlights from the San Antonio Breast Cancer Symposium | Presentation of national meeting highlights; Hosted by Yale, attended by regional audience | 2014 |
| Pharmacology Thread Leader, YSM | Co-Leader of pharmacology curriculum for the YSM in the new curriculum | 2013 - Present |
| Yale ASCO Review 2013: Highlights of the Annual Meeting | Meeting review; Hosted by Yale, attended by regional audience | 2013 |
| Connecticut Breast Health Initiative, Inc., “CT Race in the Park” | Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation | 2013 |
| Yale Cancer Center Evening Oncology Series: Breast Cancer, “An Update from the San Antonio Breast Cancer Symposium” | Review of national meeting; Hosted by Yale, attended by regional audience | 2013 |
| Curriculum Rebuild Advisory Group, YSM | Committee charged with creating a new curriculum for YSM; my design proposal was instrumental in the new YMS curriculum | 2013 - 2014 |
| Yale Cancer Center Breast Cancer Retreat, “Breast Oncology Clinical Trial Portfolio” | Presentation on Yale breast cancer clinical trials to regional oncologists | 2012 |
| Clinical Reasoning Goals Committee, YSM | Committee charged with drafting guidelines for the teaching of clinical reasoning in the YSM new curriculum | 2012 - 2014 |
| Clerkship Component Committee, YSM | Committee charged with drafting structure of YSM clerkships in the new curriculum | 2012 - 2014 |
| EPIC Steering Committee for Smilow Cancer Hospital | Committee to make recommendations about new electronic medical record system specific for Smilow Cancer Hospital | 2012 - 2013 |
| Master Course Committee, YSM | Committee charged with structuring the new courses for the new curriculum for YSM; my design proposal was instrumental in the new YMS curriculum | 2012 - 2013 |
| Yale ASCO Review 2012: Highlights of the Annual Meeting | Meeting review; Hosted by Yale, attended by regional audience | 2012 |
| Connecticut Breast Health Initiative, Inc., “CT Race in the Park” | Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation | 2012 |
| Yale Medical Student Thesis Awards Committee | Member | 2012 - Present |
| Connecticut Breast Health Initiative, Inc., Program for Donors | Invited guest researcher/speaker at dinner event to thank donors, for a breast cancer research grant awarding foundation | 2012 |
| Women’s Health Research at Yale | Grant reviewer | 2012 |
| Yale Cancer Center Evening Oncology Series: Breast Cancer, “New Agents for the Treatment of Breast Cancer” | Lecture in Yale Cancer Center seminar series for practicing oncologists; Hosted by Yale, attended by regional audience | 2012 |
| Connecticut Breast Health Initiative, Inc., “CT Race in the Park” | Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation | 2011 |
| Connecticut Breast Health Initiative, Inc., Program for Donors | Invited guest researcher/speaker at dinner event to thank donors, for a breast cancer research grant awarding foundation | 2011 |
| Yale Cancer Center Clinical Research Program in Breast Cancer | Served as Interim Program Leader for the Yale Cancer Center Breast Cancer Program | 2011 - 2012 |
| Yale Cancer Center Oncology Series: Breast Cancer, “Case Study: Caring for Locally Advanced Disease” | Yale Cancer Center seminar series for practicing oncologists; Hosted by Yale, attended by regional audience | 2010 |
| Breast Center Smilow Cancer Hospital Steering Committee | Committee to govern policy for Smilow Cancer Hospital Breast Center | 2010 - 2017 |
| Breast Cancer Research and Treatment | Reviewer | 2010 - Present |
| High school student laboratory research mentor | Mentored high school student to conduct summer research project in my lab | 2010 |
| WNPR Health Forum Radio Program “Yale Cancer Center Answers” | Guest interview on Yale radio program | 2010 |
| Connecticut Breast Health Initiative, Inc., “CT Race in the Park” | Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation | 2010 |
| Connecticut Breast Health Initiative, Inc., Program for Donors | Invited guest researcher/speaker at dinner event to thank donors, for a breast cancer research grant awarding foundation | 2010 |
| “Hope, Not Fear” Fourth Annual Breast Cancer Community Forum, “What Is Breast Cancer” | Invited speaker at community breast cancer forum | 2009 |
| Connecticut Breast Health Initiative, Inc., Howard H. Belkin Memorial Golf Tournament | Invited guest researcher/speaker at fundraising golf tournament for a breast cancer research grant awarding foundation | 2009 |
| Connecticut Breast Health Initiative, Inc., “CT Race in the Park” | Invited guest researcher/speaker at fundraising race for a breast cancer research grant awarding foundation | 2009 |
| WNPR Health Forum Radio Program “Yale Cancer Center Answers” | Guest interview on Yale radio program | 2009 |
| Current Pharmacogenomics and Personalized Medicine | Reviewer | 2009 - Present |
| Connecticut Breast Health Initiative, Inc., Program for Donors | Invited guest researcher/speaker at dinner event to thank donors, for a breast cancer research grant awarding foundation | 2009 |
| Women’s Health Research at Yale, Community Council, “Innovations in Cancer Treatment: Why a Breast Cancer Doctor is Studying Lung Cancer” | Invited lecture to a women's health research council; Hosted by Yale, attended by regional audience | 2008 |
| “Medical Files” Saudi Arabian Channel 2 Television Program, Riyadh, Kingdom of Saudi Arabia | Invited interviewed guest on television program | 2008 |
| “Hope, Not Fear” Third Annual Breast Cancer Community Forum, “What Is Breast Cancer” | Invited speaker at community breast cancer forum | 2008 |
| Pharmacology Curriculum Director, YSM | Leadership of all teaching of pharmacology to Yale medical students | 2008 - 2016 |
| Strategic Planning Committee, YSM | As a curriculum director for YSM, served on this strategic planning committee who was charged with creating a new vision for medical curriculum at YSM going forward; lead to an entirely reformed, rebuilt curriculum | 2008 - 2011 |
| Donaghue Women’s Health Grants at Yale | Grant reviewer | 2008 |
| WNPR Health Forum Radio Program “Yale Cancer Center Answers” | Guest interview on Yale radio program | 2007 |
| Molecular Cancer Research | Reviewer | 2007 - Present |
| American Cancer Society, Laboratory Tours and Lecture for Donors | Lecture and tour of my lab for major donors to American Cancer Society | 2007 |
| YSM Curriculum Director, Director of Modules (Pathophysiology) | Served as YSM curriculum director overseeing all clinical Modules in the pre-clerkship curriculum (pathophysiology courses) | 2007 - 2016 |
| Curriculum Committee, YSM | As a curriculum director, serve on this committee that oversees YSM curriculum | 2007 - 2016 |
| Module Review Committee, YSM | As Director of Modules (Pathophysiology) for the YSM curriculum, I chaired this committee that critically reviewed all Modules | 2007 - 2015 |
| Module Directors Meetings | As Director of Modules (Pathophysiology) for YSM, I chaired this monthly meeting of all Module Directors | 2007 - 2015 |
| Education Policy Committee, YSM | As a curriculum director for YSM, served on this committee that oversees all YSM education policy | 2007 - 2014 |
| “21st Century Conversations” CTV Television Program, New Haven CT | Invited interviewed guest on television program | 2007 |
| American Cancer Society, Laboratory Tours and Lecture for Donors | Lecture and tour of my lab for major donors to American Cancer Society | 2006 |
| Cancer Research | Reviewer | 2006 - Present |
| Susan G. Komen Breast Cancer Foundation, “Breast Cancer: Survive and Conquer” Symposium | Invited lecturer for breast cancer foundation | 2006 |
| American Cancer Society, Lecture, Fundraising Event for new building in CT | Lecture at American Cancer Society fundraising event | 2006 |
| Healthline WTIC Radio Program, Farmington CT | Guest interview on Yale radio program | 2006 |
| Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium, Keynote Address | Keynote speaker for Y-ME national breast cancer organization symposium | 2005 |
| American Cancer Society, Colleges Against Cancer, Breast Cancer Awareness | Served as panelist for American Cancer Society breast cancer awareness event | 2005 |
| American Cancer Society, Laboratory Tours and Lecture for Donors | Lecture and tour of my lab for major donors to American Cancer Society | 2005 |
| American Cancer Society, “Broadway on Beachside” Fundraising Event | Invited grant recipient at American Cancer Society fundraising event | 2005 |
| Breast Cancer Tumor Board, Yale Cancer Center | Chair of this meeting where all new or challenging cases of breast cancer are presented in a multidisciplinary format for treatment recommendations and planning | 2005 - Present |
| Breast Cancer Tumor Board, Yale Cancer Center | Chair of this meeting where all new or challenging cases of breast cancer are presented in a multidisciplinary format for treatment recommendations and planning | 2005 - Present |
| American Cancer Society, Laboratory Tours and Lecture for Donors | Lecture and tour of my lab for major donors to American Cancer Society | 2004 |
| American Cancer Society, “Table of Ten” Fundraising Dinner | Invited grant recipient at American Cancer Society fundraising event | 2004 - 2010 |
| Swebilius Translational Cancer Research Awards at Yale | Grant reviewer | 2004 |
| Yale-New Haven Breast Center CME Symposium: Update on Breast Disease 2004 – Multidisciplinary Breast Tumor Board | Yale breast cancer CME event; Hosted by Yale, attending by regional audience | 2003 |
| American Cancer Society, Laboratory Tours and Lecture for Donors | Lecture and tour of my lab for major donors to American Cancer Society | 2003 |
| Oncology Research | Reviewer | 2003 - Present |
| American Cancer Society, “Broadway on Beachside” Fundraising Event | Invited grant recipient at American Cancer Society fundraising event | 2003 |
| British Journal of Cancer | Reviewer | 2003 - Present |
| Clinical Cancer Research | Reviewer | 2003 - Present |
| Connecticut State Breast Cancer Research Awards | Grant reviewer | 2003 |
| Brown-Cox Awards | Grant reviewer | 2003 |
| American Cancer Society, Laboratory Tours and Lecture for Donors | Lecture and tour of my lab for major donors to American Cancer Society | 2002 |
| American Cancer Society, “Broadway on Beachside” Fundraising Event | Invited grant recipient at American Cancer Society fundraising event | 2002 |
| The FASEB Journal | Reviewer | 2002 - Present |
| Department of Defense, Breast Cancer Research Program “Pathobiology 1” | Study section grant reviewer, "Pathobiology 1" | 2001 |
| Breast Cancer Research Program, Yale Cancer Center | Served as Co-Director of the Yale Cancer Center's Breast Cancer Research Program | 2001 - 2008 |
| Journal of Clinical Oncology | Reviewer | 2001 - Present |
| Yale Pathology Series on Contemporary Issues in Diagnostic Assessment - Detection, Treatment and Prevention of Breast Cancer: A Molecular Perspective | Lecture in Yale pathology seminar series; Hosted by Yale, attended by regional audience | 1999 |
| Oncology Module Course Director, YSM | Director of oncology course for YSM medical students | 1999 - 2016 |
| Protocol Review Committee, Yale Cancer Center | Committee that critically reviews and is required to approve all clinical trials in the Yale Cancer Center | 1999 - 2014 |
| The Claire C. Courtney Breast Cancer Foundation | Invited lecture for a breast cancer foundation | 1999 |
| Y-ME National Breast Cancer Organization, Connecticut Affiliate, Annual Breast Cancer Symposium, Keynote Address | Keynote speaker for Y-ME national breast cancer organization symposium | 1998 |
| Pharmacology course YSM, Seminar conference leader | Lead cancer therapeutics small group seminar selective in YSM pharmacology course | 1998 - 2016 |
| Medical Oncology New Patient Intake Conference, Yale Cancer Center | Discussant/Conference Leader for this series in which medical oncology fellows present new patients they have seen for educational discussion | 1998 - 2007 |
| Medical Oncology Fellowship Seminar Series | Lecturer in Yale Medical Oncology Fellowship Seminar Series | 1998 - Present |
| Yale Breast Cancer Research Program Developmental Funds Awards | Grant reviewer | 1998 |
| Yale Affiliated Hospitals and Faculty Resource Program | Lecturer for the Yale Affiliated Hospitals and Faculty Resource Program | 1997 - Present |
| Yale Cancer Center | Member of Yale Cancer Center | 1997 - Present |
| Biochemical Pharmacology | Reviewer | 1997 - Present |
| The Journal of Clinical Investigation | Reviewer | 1997 - Present |
| Journal of Clinical Gastroenterology | Reviewer | 1997 - Present |
| Laboratory Investigation | Reviewer | 1997 - Present |
| Molecular Diagnosis | Reviewer | 1997 - Present |
Departments & Organizations
- Cancer Signaling Networks
- Center for Breast Cancer
- Internal Medicine
- MD Program
- Medical Oncology
- Molecular Medicine, Pharmacology, and Physiology
- Office of Curriculum
- Pusztai Lab
- Subset Medical Oncology Faculty
- WHRY Pilot Project Program Investigators
- Women's Health Research at Yale
- Yale Cancer Center
- Yale Combined Program in the Biological and Biomedical Sciences (BBS)
- Yale Medicine
- Yale Ventures